



(12) Translation of
European patent specification

(11) NO/EP 2187742 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 407/12 (2006.01)
A61K 31/351 (2006.01)
A61P 3/10 (2006.01)
C07D 309/10 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.02.26
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.10.25
(86)	European Application Nr.	08798514.9
(86)	European Filing Date	2008.08.22
(87)	The European Application's Publication Date	2010.05.26
(30)	Priority	2007.08.23, US, 957625 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
	Designated Extension States:	AL BA MK RS
(73)	Proprietor	Theracos Sub, LLC, 225 Cedar Hill Street, Suite 200, Marlborough, MA 01752, US-USA
(72)	Inventor	SONG, Yanli, Room 401Building 111166 Guanglan Rd.Pudong New District, Shanghai 201210, CN-Kina CHEN, Yuanwei, 15 Blue Ridge Lane, North Haven, Connecticut 06473, US-USA CHENG, Huawei, Room 9014, 2000 DongLu RoadPudong New District, Shanghai 201206, CN-Kina LI, Shengbin, Room 303Building 282000 Lingshan Rd.Pudong New District, Shanghai 200136, CN-Kina WU, Yuelin, Room 5022169 South Pudong Rd.Pudong New District, Shanghai 200127, CN-Kina FENG, Yan, 850 Elizabeth Street, 2nd Floor, Ridgefield, New Jersey 07657, US-USA LV, Binhua, Room 1303Building 42825 Chenhui Rd.2nd Zhangjiang Tomson GardenPudong New District, Shanghai 201203, CN-Kina XU, Baihua, Room 502Building 91152 East Huaxia Rd.Pudong New Area, Shanghai 201200, CN-Kina SEED, Brian, 2 Hawthorne Place Apt. 2J, Boston, Massachusetts 02114, US-USA HADD, Michael J., 4510 Brighton Ave., San Diego, California 92107, US-USA DU, Jiyan, Room 102Building 49420 Qinghe Rd.Jiading District, Shanghai 201800, CN-Kina WANG, Congna, Room 301Building 3785 Xinde Rd.Chuansha TownPudong New District, Shanghai 201203, CN-Kina ROBERGE, Jacques Y., Unit 19, No.301 Shimao Lakeside,Lane 188 Ming Yue Road., Shanghai 200135, CN-Kina

(74) Agent or Attorney


ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

-
- (54) Title **(2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES**
- (56) References
- Cited: US-A1- 2005 209 166


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV


1. Forbindelse som har en formel fremstilt nedenfor eller er et farmasøytisk akseptabelt salt derav:



5 (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(2-metoksyetoksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




(2S,3R,4R,5S,6R)-2-(3-(4-(2-(allyloxy)etoksy)benzyl)-4-klorfenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




10


(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(prop-2-ynyloksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(1-(prop-2-ynyloksy)propan-2-yloksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




- 5 (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(syklopentyl)oksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-syklopropoksyetoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(2,2,2-trifluoretoksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




- 5 (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(2-fluoretoksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(2,2-difluoretoksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;

**CH**


(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(2-(pyrrolidin-1-yl)etoksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;

**CK**


- 5 (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-((R)-tetrahydrofuran-3-yloksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;

**CM**

(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-syklobutoksyetoksy)etoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




(2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-(1-metylsyklopropoksy)etoksy))benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol;




- 5 (2S,3R,4R,5S,6R)-2-(4-klor-3-(4-(2-syklopropoksypropoksy)benzyl)fenyl)-6-(hydroksymetyl)tetrahydro-2H-pyran-3,4,5-triol.

2. Forbindelse ifølge krav 1, som har formelen:



- 10 eller er et farmasøytisk akseptabelt salt derav.

3. Forbindelse ifølge krav 1 som har formelen



4. Farmasøytisk sammensetning som omfatter en farmasøytisk akseptabel bærer og en forbindelse ifølge krav 1.

5. Farmasøytisk sammensetning som omfatter en farmasøytisk akseptabel bærer og en forbindelse ifølge krav 2.

6. Farmasøytisk sammensetning som omfatter en farmasøytisk akseptabel bærer og en forbindelse ifølge krav 3.

10

7. Forbindelse ifølge ett av kravene 1 til 3 for anvendelse i en fremgangsmåte for behandling av en sykdom eller tilstand som er berørt av hemming av SGLT.

8. Forbindelse for anvendelsen ifølge krav 7, hvori sykdommen eller tilstanden velges fra gruppen som består av diabetes mellitus type 1, diabetes mellitus type 2, hyperglykemi, diabetiske komplikasjoner, insulinresistens, metabolsk syndrom, hyperinsulinemi, hypertensjon, hyperurikemi, fedme, ødem, dyslipidemi, kronisk hjertesvikt og aterosklerose.

9. Forbindelse ifølge krav 1 for anvendelse i en fremgangsmåte for behandling av diabetes.

10. Forbindelse for anvendelse som definert i krav 9, hvori diabetesen er diabetes mellitus type 1.

25

11. Forbindelse for anvendelse som definert i krav 9, hvori diabetesen er diabetes mellitus type 2.

12. Forbindelse for anvendelse som definert i ett av kravene 9 til 11, hvori
5 forbindelsen administreres i kombinasjon med et andre terapeutisk middel.

13. Forbindelse for anvendelse som definert i krav 12, hvori det andre terapeutiske midlet velges fra antidiabetiske midler, lipidsenkende/lipidmodulerende midler, midler for behandling av diabetiske komplikasjoner, anti-fedme midler, antihypertensive midler,
10 antihyperurikemiske midler, og midler for behandling av kronisk hjertesvikt, aterosklerose eller relaterte forstyrrelser.

14. Forbindelse for anvendelsen definert i ett av kravene 9 til 13, som er en
forbindelse ifølge krav 2.

15

15. Forbindelse for anvendelsen definert i ett av kravene 9 til 13, som er en
forbindelse ifølge krav 3.